Updated Mar 23, 2026 by Toho Holdings
Toho Holdings reported a 0.4% decline in net sales to 593,635 million yen and a 12.0% drop in operating income to 4,804 million yen for the first half of the fiscal year ending March 2019.
The dispensing pharmacy business saw a sharp 84.5% decline in segment income to 201 million yen, primarily driven by government-mandated dispensing fee revisions.
Pharmaceutical wholesaling remained the company's core revenue driver with 571,243 million yen in net sales and a 9.9% increase in segment income.
Financial results were negatively impacted by a 7.48% reduction in National Health Insurance (NHI) drug prices and broader reforms to the Japanese drug pricing system.
Management maintained its full-year earnings projections as originally announced in May 2018, despite the challenging operating environment.
Strategic infrastructure investments included the launch of a new operation base in the Hokuriku region and a highly functional distribution center in Hiroshima to improve disaster resilience and productivity.
The company is actively expanding its generic drug market presence through its subsidiary, Kyosomirai Pharma Co., Ltd.
Toho Holdings reported a 0.4% decline in net sales to 593,635 million yen and a 12.0% drop in operating income to 4,804 million yen for the first half of the fiscal year ending March 2019.
The dispensing pharmacy business saw a sharp 84.5% decline in segment income to 201 million yen, primarily driven by government-mandated dispensing fee revisions.
Pharmaceutical wholesaling remained the company's core revenue driver with 571,243 million yen in net sales and a 9.9% increase in segment income.
Financial results were negatively impacted by a 7.48% reduction in National Health Insurance (NHI) drug prices and broader reforms to the Japanese drug pricing system.
Management maintained its full-year earnings projections as originally announced in May 2018, despite the challenging operating environment.
Strategic infrastructure investments included the launch of a new operation base in the Hokuriku region and a highly functional distribution center in Hiroshima to improve disaster resilience and productivity.
The company is actively expanding its generic drug market presence through its subsidiary, Kyosomirai Pharma Co., Ltd.